These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27341077)

  • 1. Lichenoid drug eruption associated with Bendamustine.
    Kusano Y; Terui Y; Yokoyama M; Hatake K
    Blood Cancer J; 2016 Jun; 6(6):e438. PubMed ID: 27341077
    [No Abstract]   [Full Text] [Related]  

  • 2. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
    Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
    Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
    Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 6. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
    Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
    [No Abstract]   [Full Text] [Related]  

  • 7. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
    Higo T; Miyagaki T; Nakamura F; Shinohara A; Asano H; Abe H; Senda N; Yoshizaki A; Fukayama M; Kurokawa M
    Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
    Lucijanic M; Jaksic O
    Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
    Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
    [No Abstract]   [Full Text] [Related]  

  • 10. A rare composite lymphoma: follicular and in situ mantle cell.
    Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
    Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
    Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
    Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Alnuaimi K; Lavolé J; Lascoux-Combes C; Roque Afonso AM; Sogni P; Pol S; Mallet V
    Hepatology; 2018 Jun; 67(6):2468-2470. PubMed ID: 29194671
    [No Abstract]   [Full Text] [Related]  

  • 13. Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
    Hague JS; Ilchyshyn A
    Clin Exp Dermatol; 2007 Jan; 32(1):102-3. PubMed ID: 16879449
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral lichenoid eruption associated with imatinib treatment.
    Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
    Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
    Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
    Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
    [No Abstract]   [Full Text] [Related]  

  • 16. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature.
    Fox GN; Harrell CC; Mehregan DR
    Cutis; 2005 Jul; 76(1):41-5. PubMed ID: 16144288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lichenoid drug eruption induced by spironolactone.
    Schön MP; Tebbe B; Trautmann C; Orfanos CE
    Acta Derm Venereol; 1994 Nov; 74(6):476. PubMed ID: 7701889
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 19. Lichenoid drug eruption due to cyanamide.
    Aguilar A; Gallego MA; Piqué E
    Int J Dermatol; 1999 Dec; 38(12):950-1. PubMed ID: 10671100
    [No Abstract]   [Full Text] [Related]  

  • 20. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Mulay S; Boruchov A
    Leuk Lymphoma; 2015 Mar; 56(3):805-7. PubMed ID: 24913498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.